[1] Siege R L, Fedewa S A, Miller K D, et al. Cancer statistics for hipanic-s/latinos[J]. CA Cancer J Clin,2015, 65(6):457-480. [2] 周晖,刘昀昀,林仲秋.《2017 NCCN宫颈癌临床实践指南》解读[J].中国实用妇科与产科杂志,2017, 33(1):100-107. [3] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-386. [4] McCormack P L. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)):a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts[J]. Drugs, 2014,74(11):1253-1283. [5] Malagon T, Drolet M, Boily M C, et al. Cross-protective efficacy of two human papillomavirus vaccines:asystematic review and meta-analysis[J]. Lancet Infect Dis, 2012,12(10):781-789. [6] Jiang B, Xue M. Correlation of E6 and E7 levels in high-risk HPV 16 type cer-vical lesions with CCL20 and Langerhans cells[J].Genet Mol Res, 2015, 14(3):10473-10481. [7] De Oliveira L M, Morale M G, Chaves A A, et al. Design, immune responses and anti-tumor potential of an HPV16 E6 E7 multi-epitope vaccine[J].PLoS One,2015,10(9):e0138686. [8] 王培龙,段建敏. 脑组织特异性血管生成抑制因子1(BAll)的研究进展[J].国际泌尿系统杂, 2013, 33(4):543-545. [9] 安振,万艳平. HPV 16 E6蛋白在宫颈癌中的作用研究进展[J]. 微生物学免疫学进展,2015,43(3):42-46. [10] Wang N, Zhan T, Ke T, et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer[J].Br J Cancer, 2014, 110(4):1034-1044. [11] Bodily J M, Mehta K P, Laimins L A. Human papillomavirus E7 enhances hpoxia inducible factor 1 mediated transcription by inhibiting bingdingog histone deacetylases[J]. Cancer Res, 2011, 71(3):1187-1195. [12] 谢幸,苟文丽,林仲秋. 妇产科学[M]. 北京:人民卫生出版社, 2013:306. [13] 何华. 如何正确地对免疫组化结果进行半定量评分[J]. 中外健康文摘临床医师, 2008, 5(7):162. [14] Hanahan D, Weinberg R A. Hallmarks of cancer:the next generation[J]. Cell, 2011, 144(5):646-674. [15] 王广娇,杨欣,郝敏. 血管内皮生长因子A在宫颈癌发病机制中的研究进展[J].国际妇产科学杂志, 2016,43(5):519-523. [16] Nishimori H, Shiratsuchi T, Urano T, et al. A novel brain-specific p53-target gene, BAI-1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis[J]. Oncogene, 1997, 15(18):2145-2150. [17] Meisen W H, Dubin S, Sizemore S T, et al. Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targetedtherapies[J]. Mol Cancer Ther, 2015, 14(1):307-314. [18] 田大伟,孙岩,杨宇明,等. BAI-1在肾细胞癌组织中的表达定位及与VEGF、MCD P53蛋白相关性研究[J].中国肿瘤临床,2013,40(6):336-340. [19] Izutsu T, Konda R, Sugimura J, et al. Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma[J]. J Urol, 2011, 185(6):2353-2358. [20] 王志华, 康熙雄,张智清,等. 肠癌细胞BAI1基因表达的检测及其抗肿瘤作用[J]. 世界华人消化杂志,2003,11(6):834-836. [21] 刘芳,部晶,张鹏,等. 结直肠异常隐窝灶中BAI1、VEGF蛋白表达及意义[J]. 临床与实验病理学杂志,2016,32(8):856-859. [22] Ou Y H, Chung P H, Hsu F F, et al. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1[J]. EMBO J, 2007, 26(17):3968-3980. [23] Tomanek R J, Christensen L P, Simons M, et al. Embryonic coronary vasculogenesis and angiogenesis are regulated by interactions between multiple FGFs and VEGF and are influenced by mesenchymal stem cells[J]. Dev Dyn, 2010, 239(12):3182-3191. [24] Shaikh F, Sanehi P, Rawal R. Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53-E6 in HPV[J]. Bioinformation, 2012, 8(13):607-612. |